Offering was conducted alongside IPO, at same price
By Devika Patel
Knoxville, Tenn., Oct. 11 - Regulus Therapeutics Inc. said it settled a $25 million private placement of stock with AstraZeneca AB in connection with its $45 million initial public offering of stock on Oct. 10, according to an 8-K filed Thursday with the Securities and Exchange Commission. The IPO priced with a $6.75 million greenshoe on Oct. 4.
In the private placement, the company sold 6.25 million common shares at $4.00 per share, which is the same price as the shares sold in the IPO.
The biopharmaceutical company focused on drugs that target microRNAs is based in San Diego.
| Issuer: | Regulus Therapeutics Inc.
|
| Issue: | Common stock
|
| Amount: | $25 million
|
| Shares: | 6.25 million
|
| Price: | $4.00
|
| Warrants: | No
|
| Investor: | AstraZeneca AB
|
| Pricing date: | Oct. 4
|
| Settlement date: | Oct. 10
|
| Stock exchange: | Nasdaq: RGLS
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
